Outlook of Diabetic Macular Edema – Current Landscape and the Way ForwardLONG-LASTING VEGF BLOCKERS, COMPOUNDS WITH VEGF- INDEPENDENT MECHANISM AND, TOPICAL AND ORAL TREATMENT OPTIONS, BRING THE QUEST FOR THE “IDEAL RETINAL DRUG” A STEP CLOSER
No. of Pages: 81
Global market for DME was ~$3.7 billion in 2019 with US alone contributing to 51% market share, owing to the higher incidence rates of diabetes
|
03-Jul-2020
|
4500
|
Next Decade Generic String Of Pearls Opportunities: Sustainability Assessment With Respect To Therapeutic Positioning
No. of Pages: 127
The rapid growth of the generic industry has come with a number of challenges, such as heavy competition, including from authorized generics and government-mandated price
|
24-Nov-2017
|
4000
|
The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
No. of Pages: 104
"The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to
|
13-Oct-2017
|
4000
|
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game
No. of Pages: 128
In 2016, encouraging uptake of Lantus BS in Japan confirms strong foothold of the marketer, product mix targeted to DPC hospitals (Diagnostic Procedure Combination hospitals-
|
14-Aug-2017
|
4,000
|
Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population
No. of Pages: 200
Increase in prevalence of Prostate cancer and availability of new treatment options (Zytiga, Xtandi, Cabazitaxel and Xofigo) in last few years has extended role of
|
01-Feb-2017
|
4500
|
Xtandi- The Real Potential and the Astellas Part!
No. of Pages: 12
Xtandi- The Real Potential and the Astellas Part!
Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to treat prostate cancer
|
19-Apr-2013
|
500
|
MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!
No. of Pages: 9
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues
|
10-Apr-2013
|
500
|
New Technologies Initiative: Gateway to Treating Genetic Diseases - Sarepta Therapeutics - Skipping Makes Sense - Restoring Muscle Function in Duchenne Muscular Dystrophy
No. of Pages: 18
Approval of KYNAMRO (ISIS/Sanofi, HoFH), a first systemic Oligonucleotide Antisense (ASO) based therapy has raised expectations from the compounds in pipeline of other companies with
|
01-Mar-2013
|
500
|
TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed
No. of Pages: 14
TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic
|
22-Jul-2013
|
800
|
Therapeutic Class Report Overview - Future Of GPR Agonist
No. of Pages: 20
Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of
|
04-Feb-2013
|
1000
|
